A computational analysis of the binding model of MDM2 with inhibitors

It is a new and promising strategy for anticancer drug design to block the MDM2-p53 interaction using a non-peptide small-molecule inhibitor. We carry out molecular dynamics simulations to study the binding of a set of six non-peptide small-molecule inhibitors with the MDM2. The relative binding free energies calculated using molecular mechanics Poisson–Boltzmann surface area method produce a good correlation with experimentally determined results. The study shows that the van der Waals energies are the largest component of the binding free energy for each complex, which indicates that the affinities of these inhibitors for MDM2 are dominated by shape complementarity. The A-ligands and the B-ligands are the same except for the conformation of 2,2-dimethylbutane group. The quantum mechanics and the binding free energies calculation also show the B-ligands are the more possible conformation of ligands. Detailed binding free energies between inhibitors and individual protein residues are calculated to provide insights into the inhibitor-protein binding model through interpretation of the structural and energetic results from the simulations. The study shows that G1, G2 and G3 group mimic the Phe19, Trp23 and Leu26 residues in p53 and their interactions with MDM2, but the binding model of G4 group differs from the original design strategy to mimic Leu22 residue in p53.Graphical AbstractThe G1, G2 and G3 group of a group inhibitors mimic the Phe19, Trp23 and Leu26 residues in p53 and their interactions with MDM2, but the binding model of G4 group of inhibitor 8 differs from the original design strategy to mimic Leu22 residue in p53.

[1]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[2]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[3]  S. Sebti,et al.  Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction. , 2005, Angewandte Chemie.

[4]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[5]  John Z H Zhang,et al.  Selectivity of neutral/weakly basic P1 group inhibitors of thrombin and trypsin by a molecular dynamics study. , 2008, Chemistry.

[6]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[7]  P. Meltzer,et al.  Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.

[8]  P. Kollman,et al.  Biomolecular simulations: recent developments in force fields, simulations of enzyme catalysis, protein-ligand, protein-protein, and protein-nucleic acid noncovalent interactions. , 2001, Annual review of biophysics and biomolecular structure.

[9]  Masayuki Hata,et al.  Computational simulations of HIV-1 proteases--multi-drug resistance due to nonactive site mutation L90M. , 2006, Journal of the American Chemical Society.

[10]  Jonathan W. Essex,et al.  Monte Carlo Simulations for Proteins: Binding Affinities for Trypsin−Benzamidine Complexes via Free-Energy Perturbations , 1997 .

[11]  Masayuki Hata,et al.  Mechanism of drug resistance due to N88S in CRF01_AE HIV-1 protease, analyzed by molecular dynamics simulations. , 2007, Journal of medicinal chemistry.

[12]  F. J. Luque,et al.  Role of stacking interactions in the binding sequence preferences of DNA bis-intercalators: insight from thermodynamic integration free energy simulations , 2005, Nucleic acids research.

[13]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[14]  David S. Goodsell,et al.  A semiempirical free energy force field with charge‐based desolvation , 2007, J. Comput. Chem..

[15]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[16]  N. Davidson,et al.  Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents. , 2003, Journal of Medicinal Chemistry.

[17]  Ray Luo,et al.  Accelerated Poisson–Boltzmann calculations for static and dynamic systems , 2002, J. Comput. Chem..

[18]  P. Kollman,et al.  Computational study of protein specificity: The molecular basis of HIV-1 protease drug resistance , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[19]  A. Levine,et al.  Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. , 1994, Genes & development.

[20]  D. Case.  Normal mode analysis of protein dynamics , 1994 .

[21]  Chang-Guo Zhan,et al.  Microscopic modes and free energies of 3-phosphoinositide-dependent kinase-1 (PDK1) binding with celecoxib and other inhibitors. , 2006, The journal of physical chemistry. B.

[22]  D. Lane,et al.  Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides. , 1994, Oncogene.

[23]  P. Kollman,et al.  A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .

[24]  J. Trujillo-Ferrara,et al.  Conformational changes of the p53-binding cleft of MDM2 revealed by molecular dynamics simulations. , 2006, Biopolymers.

[25]  Wei Zhang,et al.  A point‐charge force field for molecular mechanics simulations of proteins based on condensed‐phase quantum mechanical calculations , 2003, J. Comput. Chem..

[26]  Peter V Coveney,et al.  Rapid and accurate prediction of binding free energies for saquinavir-bound HIV-1 proteases. , 2008, Journal of the American Chemical Society.

[27]  A. Levine,et al.  The p53-mdm-2 autoregulatory feedback loop. , 1993, Genes & development.

[28]  K. Sharp,et al.  Accurate Calculation of Hydration Free Energies Using Macroscopic Solvent Models , 1994 .

[29]  Tingjun Hou,et al.  Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance. , 2007, Journal of medicinal chemistry.

[30]  P. Chène.  Inhibiting the p53–MDM2 interaction: an important target for cancer therapy , 2003, Nature Reviews Cancer.

[31]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[32]  Tong Zhu,et al.  Some insights into mechanism for binding and drug resistance of wild type and I50V V82A and I84V mutations in HIV-1 protease with GRL-98065 inhibitor from molecular dynamic simulations. , 2010, European journal of medicinal chemistry.

[33]  Ray Luo,et al.  Binding induced folding in p53-MDM2 complex. , 2007, Journal of the American Chemical Society.

[34]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[35]  P. Kollman,et al.  Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.

[36]  M. Sanner,et al.  Reduced surface: an efficient way to compute molecular surfaces. , 1996, Biopolymers.

[37]  Su Qiu,et al.  Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. , 2006, Journal of medicinal chemistry.

[38]  J. Deschamps,et al.  Structure-based design of potent non-peptide MDM2 inhibitors. , 2005, Journal of the American Chemical Society.

[39]  Kun Song,et al.  Insight through molecular mechanics Poisson-Boltzmann surface area calculations into the binding affinity of triclosan and three analogues for FabI, the E. coli enoyl reductase. , 2006, Journal of medicinal chemistry.

[40]  David S. Goodsell,et al.  Grid-Based Hydrogen Bond Potentials with Improved Directionality , 2004 .

[41]  Maxwell D Cummings,et al.  Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. , 2005, Journal of medicinal chemistry.

[42]  P. Kollman,et al.  Computational Alanine Scanning To Probe Protein−Protein Interactions: A Novel Approach To Evaluate Binding Free Energies , 1999 .

[43]  Heather A Carlson,et al.  Small molecule inhibitors of the MDM2-p53 interaction discovered by ensemble-based receptor models. , 2007, Journal of the American Chemical Society.

[44]  L. Vassilev.  p53 Activation by small molecules: application in oncology. , 2005, Journal of medicinal chemistry.

[45]  Ye Mei,et al.  Quantum mechanical studies of residue-specific hydrophobic interactions in p53-MDM2 binding. , 2008, The journal of physical chemistry. B.

[46]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[47]  Peter A. Kollman,et al.  Application of the multimolecule and multiconformational RESP methodology to biopolymers: Charge derivation for DNA, RNA, and proteins , 1995, J. Comput. Chem..

[48]  Jeremy C. Smith,et al.  Thermodynamic stability of water molecules in the bacteriorhodopsin proton channel: a molecular dynamics free energy perturbation study. , 1996, Biophysical journal.

[49]  Shubhra Ghosh Dastidar,et al.  Forces mediating protein–protein interactions: a computational study of p53 “approaching” MDM2 , 2010 .